Metsera downgraded to Market Perform from Outperform at Leerink

Core Viewpoint - Leerink downgraded Metsera (MTSR) to Market Perform from Outperform with a price target of $57, down from $77, following Pfizer's announcement of an agreement to acquire Metsera for $4.9 billion upfront, with a total potential deal value of about $7.3 billion contingent on pipeline-related targets [1] Group 1: Acquisition Details - Pfizer announced an agreement to acquire Metsera for $4.9 billion upfront [1] - The total potential deal value could reach approximately $7.3 billion, depending on the achievement of various pipeline-related targets [1] Group 2: Future Revenue Potential - Metsera's novel obesity pipeline is expected to drive Pfizer's revenue growth beyond 2028 [1] - The analyst believes that Metsera's assets could collectively generate more than $5 billion in peak sales [1]